Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Real-time Estimate Cboe BZX  -  09:25 2022-12-06 am EST
283.09 USD   -0.64%
01:42aMirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
RE
12/05Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
RE
12/05Better days ahead?
MS
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Atlantic Equities Adjusts Amgen's Price Target to $182 from $190, Keeps Underweight Rating

08/09/2022 | 11:06am EST


ę MT Newswires 2022
All news about AMGEN INC.
01:42aMirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
RE
12/05Mirati to focus adagrasib/Keytruda study in low PDL1 lung cancer patients
RE
12/05Better days ahead?
MS
12/05Juno Therapeutics Requests That The Supreme Court Wait To Make A Decision On Its Writte..
AQ
12/05Amgen : WCIRDC Presentation
PU
12/05Transcript : Amgen Inc. - Special Call
CI
12/05Johnson & Johnson's Janssen Global Services Unit Says No Plans to Bid for Horizon Thera..
MT
12/03Amgen says experimental obesity drug has promising durability
RE
12/03J&J unit says does not intend to bid for Horizon Therapeutics
RE
12/03J&J unit says does not intend to bid for Horizon Therapeutics
RE
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 241 M - -
Net income 2022 6 552 M - -
Net Debt 2022 26 379 M - -
P/E ratio 2022 23,5x
Yield 2022 2,72%
Capitalization 152 B 152 B -
EV / Sales 2022 6,81x
EV / Sales 2023 6,50x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 24
Last Close Price 284,91 $
Average target price 259,50 $
Spread / Average Target -8,92%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.26.91%152 342
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.21.08%289 331
NOVO NORDISK A/S22.53%287 688
PFIZER, INC.-13.78%285 774